The diverse efficacy of different PPARγ agonists in NAFLD and NASH reinforces that notion that the activation of the same PPAR subtype by different agonists does not necessarily lead to similar outcomes. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.